Biohaven Acquires Glutamate-Modulating Prodrugs from ALS Biopharma

Canadian biotechnology company, Portage Biotech has announced that its subsidiary, Biohaven Pharmaceuticals, has obtained the worldwide intellectual property rights to 300 prodrugs from ALS Biopharma, an early stage biotechnology company that specializes in discovery and development of therapies for ALS. The prodrugs, which were designed by scientists from the Fox Chase Chemical Diversity Center, are new molecular entities that function as modulators of glutamate signaling. In light of the known role of glutamate excitotoxicity in the pathophysiology of ALS, these compounds are of potential interest as candidate therapies for the disease.

Click here to read the press release.

disease-als topic-preclinical topic-randd
Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail